Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Victory Capital Management Inc. boosted its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 10.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 398,866 shares of the biopharmaceutical company’s stock after purchasing an additional 37,480 shares during the quarter. Victory Capital Management Inc. owned 0.61% of Regulus Therapeutics worth $626,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 453,784 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Regulus Therapeutics during the 2nd quarter worth $352,000. Tyche Wealth Partners LLC raised its holdings in Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares in the last quarter. Rhumbline Advisers acquired a new position in Regulus Therapeutics in the 2nd quarter valued at $136,000. Finally, Renaissance Technologies LLC lifted its position in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 42,600 shares during the period. Institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Finally, Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Trading Up 7.2 %

RGLS opened at $1.64 on Friday. The company has a market cap of $107.42 million, a P/E ratio of -1.53 and a beta of 1.63. The company’s 50 day moving average is $1.53 and its 200-day moving average is $1.74. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.